WO2005023790A1 - Sel sodique d'acide (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoique - Google Patents

Sel sodique d'acide (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoique Download PDF

Info

Publication number
WO2005023790A1
WO2005023790A1 PCT/IN2003/000304 IN0300304W WO2005023790A1 WO 2005023790 A1 WO2005023790 A1 WO 2005023790A1 IN 0300304 W IN0300304 W IN 0300304W WO 2005023790 A1 WO2005023790 A1 WO 2005023790A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
butylcarbamoyl
ethoxy
phenyl
compound
Prior art date
Application number
PCT/IN2003/000304
Other languages
English (en)
Inventor
Joy Mathew
Tom Thomas Puthiaparampil
Sambasivam Ganesh
Original Assignee
Biocon Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Limited filed Critical Biocon Limited
Priority to PCT/IN2003/000304 priority Critical patent/WO2005023790A1/fr
Priority to AU2003269481A priority patent/AU2003269481A1/en
Publication of WO2005023790A1 publication Critical patent/WO2005023790A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to a novel compound and to a novel process for preparing the novel compound, to a pharmaceutical composition containing the novel compound and to the prophylactic and/or therapeutic use of the compound and composition.
  • BACKGROUND OF THE INVENTION US 5,216,167 discloses 2-ethoxy-4- ⁇ [3-methyl-l-(2-piperidin- l-yl-phenyl)-butylcarbamoyl]-methyl ⁇ -benzoic acid.
  • the compound exhibits blood-glucose lowering action with lower toxicity, and may be safely administered, orally or parenterally, as it is or advantageously as a pharmaceutical composition
  • a pharmaceutical composition comprising an effective amount of the compound or its pharmacologically acceptable salt and a pharmacologically acceptable carrier, excipient or diluent therefor, in the form of powder, granule, tablet, hard capsule, soft capsule, dry syrup, suppository, injection or the like.
  • .US 6,143,769 discloses (S)-(+)-2-ethoxy-4- ⁇ [3-methyl-l-(2- piperidin-l-yl-phenyl)-butylcarbamoyl]-methyl ⁇ -benzoic acid which is currently marketed for treatment of Type II diabetes.
  • the present invention discloses a novel salt of 2-ethoxy-4- ⁇ [3-methyl-l-(2-piperidin-l-yl-phenyl)-butylcarbamoyl]-methyl>- benzoic acid or (S)-(+)-2-Ethoxy-4- ⁇ [3-methyl-l-(2-piperidin-l-yl- phenyl)-butylcarbamoyl]-methyl ⁇ -benzoic acid, namely sodium salt of 2-ethoxy-4- ⁇ [3-methyl-l-(2-piperidin-l-yl-phenyl butylcarbamoyl]-methyl ⁇ -benzoic acid or sodium salt of (S)-(+)-2- Ethoxy-4- ⁇ [3-methyl-l-(2-piperidin-l-yl-phenyl)-butylcarbamoyl]- methyl ⁇ -benzoic acid (FORMULA I), which is useful in the , treatment of Type II diabetes.
  • This compound shows good stability in solid form. Also this compound is significantly soluble in water or aqueous media whereas the free acid, namely (S)-(+)-2-ethoxy-4- ⁇ [3-methyl-l-(2-piperidin-l-yl-phenyl)-butylcarbamoyl]-methyl ⁇ - benzoic acid, is practically insoluble in water.
  • the present invention relates to a novel compound of formula I, which is sodium salt of 2-ethoxy-4- ⁇ [3-methyl-l-(2-piperidin-l-yl- phenyl)-butylcarbamoyl]-methyl ⁇ -benzoic acid or sodium salt of (S)-(+)-2-ethoxy-4- ⁇ [3-methyl-l-(2-piperidin-l-yl-phenyl)- butylcarbamoyl]-methyl ⁇ -benzoic acid (FORMULA I), to a novel process for preparing this compound, to a pharmaceutical composition containing this compound and to the prophylactic and/or therapeutic use of the compound and composition.
  • formula I is sodium salt of 2-ethoxy-4- ⁇ [3-methyl-l-(2-piperidin-l-yl- phenyl)-butylcarbamoyl]-methyl ⁇ -benzoic acid or sodium salt of (S)-(+)-2-ethoxy-4- ⁇ [3-methyl-l-
  • the present invention provides a compound of formula I, for use in the treatment of and/or prophylaxis of hyperglycemia.
  • the stability and water solubility of this compound provides for significant advantages in formulation, bioavailability and bulk handling.
  • DETAILED DESCRIPTION OF THE INVENTION Accordingly, the present invention provides a novel compound of formula I.
  • the compound of formula I is sodium salt of 2-ethoxy-4- ⁇ [3- methyl-l-(2-piperidin-l-yl-phenyl)-butylcarbamoyl]-methyl ⁇ - benzoic acid or sodium salt of (S)-(+)-2-ethoxy-4- ⁇ [3-methyl-l-(2- piperidin-l-yl-phenyl)-butylcarbamoyl]-methyl ⁇ -benzoic acid.
  • the currently marketed (S)-(+)-2-ethoxy-4- ⁇ [3-methyl-l-(2- piperidin-l-yl-phenyl)-butylcarbamoyl]-methyl ⁇ -benzoic acid is insoluble in water (The Merck Index Online, 2003).
  • the compound of present invention is freely soluble in water. This has significant pharmacokinetic advantage and enhances bioavailability. As stated the compound of the invention is significantly soluble in water and aqueous media.
  • a convenient method for determining the stability of the compounds of the invention in aqueous solution involves determining the degree of precipitation of the parent free base from an aqueous solution of the test compound at known conditions of temperature and over known periods of time.
  • the compound of formula I show good stability in aqueous conditions.
  • the quantitative analysis of the test may be carried out using conventional methods e.g. HPLC.
  • the compound of the invention is indicated as having useful therapeutic properties.
  • the present invention accordingly provides a compound of formula I, for use as an active therapeutic substance.
  • the present invention provides a compound of formula I, for use in the treatment of and/or prophylaxis of hyperglycemia.
  • the present invention also provides a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier therefor.
  • the pharmaceutical compositions of the present invention will be adapted for oral administration, although compositions for administration by other routes, such as by injection and percutaneous absorption are also envisaged.
  • compositions for oral administration are unit dosage forms such as tablets and capsules.
  • Other fixed unit . dosage forms, such as powders presented in sachets, may also be used.
  • the present invention further provides a method for the treatment and/or prophylaxis of hyperglycemia in a human or non- human mammal, which comprises administering an effective, non- toxic, amount of a compound of formula I, to a hyperglycemic human or non-human mammal in need thereof.
  • the compound of formula I is obtained by the reaction between (S)-(+)-2-ethoxy-4- ⁇ [3-methyl-l-(2-piperidin-l-yl-phenyl)- butylcarbamoyl]-methyl ⁇ -benzoic acid and a source of sodium counter-ion.
  • the reaction is generally carried out under conventional salt forming conditions, for example by admixing (S)- (+)-2-ethoxy-4- ⁇ [3-methyl-l-(2-piperidin-l-yl-phenyl)- butylcarbamoyl]-methyl ⁇ -benzoic acid and the suitable source of counter-ion, e.g.
  • a suitable solvent generally a Cl-4 alkanolic solvent such as methanol, ethanol, other aprotic solvents like acetonitrile or water immiscible organic solvent like ethyl acetate or isobutyl acetate, at a temperature which provides a suitable rate of formation of the required product, generally at an elevated temperature and thereafter isolating the product.
  • a Cl-4 alkanolic solvent such as methanol, ethanol, other aprotic solvents like acetonitrile or water immiscible organic solvent like ethyl acetate or isobutyl acetate
  • Example 4 To a solution of 2-ethoxy-4- ⁇ [3-methyl-l-(2-piperidin-l-yl- phenyl)-butylcarbamoyl]-methyl ⁇ -benzoic acid (5 g, 0.011 mol) in ethyl acetate (50 ml), sodium carbonate (1.2 g, 0.011 mol) was added. After stirring for 3 hours, the reaction mixture was filtered to afford title compound.
  • Example 5 To a solution of 2-ethoxy-4- ⁇ [3-methyl-l-(2-piperidin-l-yl- phenyl)-butylcarbamoyl]-methyl ⁇ -benzoic acid (5 g, 0.011 mol) in methanol (50 ml), a solution of sodium hydroxide (0.44 g, 0.011 mol) in methanol (10 ml) was added. After stirring for 1 hour, the reaction mixture was concentrated and ethyl acetate (25 ml) was added under stirring. The mixture was filtered to afford title compound.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un sel sodique d'acide (s)-(+)-2-éthoxy-4-{[3-méthyl-1-(2-pipéridin-1-yl-phényl)-butylcarbamoyl]-méthyl}-benzoïque. Il fait preuve, chez les mammifères, d'une activité hypoglycémiante, et présente un intérêt prophylactique et/ou thérapeutique pour la prévention et/ou le traitement du diabète.
PCT/IN2003/000304 2003-09-10 2003-09-10 Sel sodique d'acide (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoique WO2005023790A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IN2003/000304 WO2005023790A1 (fr) 2003-09-10 2003-09-10 Sel sodique d'acide (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoique
AU2003269481A AU2003269481A1 (en) 2003-09-10 2003-09-10 (s)-(+)-2-ethoxy-4-{(3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl)-methyl}-benzoic acid sodium salt

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2003/000304 WO2005023790A1 (fr) 2003-09-10 2003-09-10 Sel sodique d'acide (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoique

Publications (1)

Publication Number Publication Date
WO2005023790A1 true WO2005023790A1 (fr) 2005-03-17

Family

ID=34259919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2003/000304 WO2005023790A1 (fr) 2003-09-10 2003-09-10 Sel sodique d'acide (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoique

Country Status (2)

Country Link
AU (1) AU2003269481A1 (fr)
WO (1) WO2005023790A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735959A (en) * 1981-01-10 1988-04-05 Dr. Karl Thomae Gmbh Carboxylic acid amides and pharmaceutical compositions containing them
US4863724A (en) * 1983-06-08 1989-09-05 Dr. Karl Thomae Gmbh Anti-diabetic pharmaceutical compositions and the preparation thereof
US5216167A (en) * 1983-12-30 1993-06-01 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
US6143769A (en) * 1983-12-30 2000-11-07 Karl Thomae Gmbh Phenylacetic acid benzylamides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735959A (en) * 1981-01-10 1988-04-05 Dr. Karl Thomae Gmbh Carboxylic acid amides and pharmaceutical compositions containing them
US4863724A (en) * 1983-06-08 1989-09-05 Dr. Karl Thomae Gmbh Anti-diabetic pharmaceutical compositions and the preparation thereof
US5216167A (en) * 1983-12-30 1993-06-01 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
US6143769A (en) * 1983-12-30 2000-11-07 Karl Thomae Gmbh Phenylacetic acid benzylamides

Also Published As

Publication number Publication date
AU2003269481A1 (en) 2005-03-29

Similar Documents

Publication Publication Date Title
CA2382886C (fr) Formulation de benzamide a activite inhibitrice d'histone deacetylase
KR100716389B1 (ko) Ｎ-히드록시－４－｛５－［４－（5－이소프로필－２－메틸－１,３－티아졸－4－일）페녹시］펜톡시｝벤즈아미딘 ２메탄술폰산염
EA021826B1 (ru) Усовершенствованный способ синтеза пирфенидона
KR20100098545A (ko) ３­（６­（１­２,２­디플루오로벤조〔ｄ〕〔１,３〕디옥솔­５­일）사이클로프로판카복스아미도）­３­메틸피리딘­２­일）벤조산의 제형
EA007613B1 (ru) Бензолсульфонатная соль (2s,4s)-1-циано-4-фтор-1-[(2-гидрокси-1,1-диметил)этиламино]ацетилпирролидина
EP0271709B1 (fr) Sel du diclofenac avec une base organique cyclique et compositions pharmaceutiques le contenant
KR20170061616A (ko) 피마살탄의 신규 염
US6670370B1 (en) Dextromethorphan tannate
AU599034B2 (en) Furosemide salts
EA014101B1 (ru) Антагонист cd80
KR800000944B1 (ko) 벤젠설포닐-우레아의 제조방법
WO2005023790A1 (fr) Sel sodique d'acide (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoique
WO2005023803A1 (fr) Sel d'acide phosphorique de 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy]phenyl]methyl]-2,4-thiazolidinedione
JP2010520236A (ja) リソフィリンアナログとその使用法
CA2549832A1 (fr) Gentisate d'amlodipine et procede de fabrication
KR102170422B1 (ko) 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물
US6784315B2 (en) Stilbene derivative crystal and method for producing the same
WO2005023789A1 (fr) Sel phosphorique de l'acide (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoique
EP0055593B1 (fr) Compositions comprenant des E-prostaglandines
JP2569060B2 (ja) グルタミルシスティン誘導体、その製造法およびそれを有効成分とする組織グルタチオンレベル向上剤
KR101006254B1 (ko) Ｎ-히드록시-4-｛5-〔4-（5-이소프로필-2-메틸-1,3-티아졸-4-일）페녹시〕펜톡시｝벤즈아미딘 2 에탄술폰산염, 이의제조방법 및 이를 포함하는 약학 조성물
WO2005021543A1 (fr) Sel d'acide phosphorique de 5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2, 4-thiazolidinedione
CN105367622B (zh) 一种阿加曲班化合物
CN112979572B (zh) 一种帕瑞昔布衍生物及其制备方法和应用
KR100632470B1 (ko) 결정성 시부트라민 캄실레이트염과 이의 제조방법

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP